Study of the effect of Memantine on negative symptoms and inflammatory biomarkers (IL6, TNFa CRP) in patients with schizophrenia or schizoaffective disorders

Phase 3

• Conditions: Schizophrenia; Schizophrenia.

• Registration Number: IRCT201310083210N5
• Lead Sponsor: Faculty of pharmacy, Shahid Beheshti University of Medical Scienses

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 59

Inclusion Criteria

patients aged 18-65 years old; patients that base on DSM V criteria has diagnosis of schizophrenia or schizoaffective disorder; patients who stable on medication four weeks prior to baseline and has not planned medication change.
Exclusion criteria: subject that organic brain disease or neurological diagnosis (including neurological disorder or an active seizure); subjects who will meet the criteria for DSM-V diagnosis of alcohol or substance dependence within the last six month; any change of psychotropic medication within the previous four weeks.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
PANSS score. Timepoint: At baseline, at the end of first and third month of the study. Method of measurement: Questionair.;Clinical evaluation. Timepoint: At baseline, at the end of first and third month of the study. Method of measurement: Questionair.

Secondary Outcome Measures

Name	Time	Method
Assessment of inflammatory biomarkers (IL6, TNF, CRP). Timepoint: At baseline, at the end of first and third month of the study. Method of measurement: ELISA.;Assessment of inflammatory biomarkers (IL6, TNF, CRP). Timepoint: At baseline, at the end of first and third month of the study. Method of measurement: ELISA.